Role of minimally invasive surgery for rectal cancer

Table 6 Selected transanal total mesorectal excision rectal cancer surgery studies

Ref.	Yr	Trial	Surgery	n	OR time (min)	EBL (mL)	CVR (%)	LOS (d)	Comp (%)	Mort (%)	DRM+ (%)	CRM+ (%)	LN	C-TME (%)	DFS (%)	OS (%)	LRR (%)
Denost et al[17]	2014	SC RCT	Lap	50	264		10	8	44	2	2	18	17	62
			TaTME	50	240		4	7	32	0	8	4	17	70
Lacy et al[31]	2015	SC O	TaTME	140			0		34			6	15	97	91	97	2.3
Chen et al[51]	2016	MC PMR	Lap	100	178	88	5	7	17			10	17
			TaTME	50	182	68	2	7	20			4	17
Marks et al[55]	2017	SC O	TaTME	373												90	7.4
Penna et al[87]	2017	MC O	TaTME	720	277		9	8	32	2	0	2	17	85
Denost et al[54]	2017	SC RCT	Lap	50											71	74	4.8
			TaTME	50											73	87	2.6
Persiani et al[42]	2018	SC PSM	Lap	46	272		20	7	21			0		84
			TaTME	46	276		0	7	23			0		87
Perdawood et al[33]	2018	SC PSM	Lap	100	334	239	11	14			1	13	22	68
			TaTME	100	285	82	0	8			0	7	22	58
			Open	100	325	704		15			1	10	18	68
Perez et al[88]	2017	SC RR	Robot	60	276		10	8	37				15	88
			TaTME	55	291		3	7	22				15	90
Detering et al[18]	2019	MC PSM	Lap	396			9	6	36	1		4
			TaTME	396			2	7	42	0		4
Law et al[34]	2019	SC PSM	Robot	40	270	150	5	6	17			1	13
			TaTME	40	254	90	5	6	12			0	13
Lee et al[19]	2019	MC PMR	Robot	453	189		4		35	0	1	6	16	95
			TaTME	277	189		3		33	0	2	6	16	92
Hol et al[56]	2019	SC O	TaTME	159					52		0	1		87	81	77	3.8
Wasmuth et al[20]	2019	MC O	TaTME	157													11.6

MC: Multicenter; RCT: Randomized controlled trial; SC: Single center; PMR: Prospective matched review; RR: Retrospective review; PSM: Propensity score matched; O: Observational study; TaTME: Transanal total mesorectal excision. OS: Overall survival; DFS: Disease-free survival; CVR: Conversion rate; Mort: Mortality; Comp: Complications; CRM: Circumferential resection margin; DRM: Distal resection margin; C-TME: Complete total mesorectal excision; LRR: Local recurrence rates.